Ustekinumab as Add-on Therapy Was Seen to Benefit SLE Patients in Phase 2 Trial
Ustekinumab as an add-on to standard of care was seen to significantly increase the number of systemic lupus erythematosus (SLE) patients with a reduction in disease activity compared to standard of care alone, results from a Phase 2 trial show. Patients were also less likely to experience a disease flare…